Skip to main content
. 2018 Mar 19;29(1):27–37. doi: 10.31138/mjr.29.1.27

Figure 5.

Figure 5.

Biologic DMARD use in RA patients.

The % use of the different biologic disease modifying anti-rheumatic drugs (bDMARDs) is shown (n=1.036, see also figure 2). TNFi, tumor necrosis factor inhibitors